Summary
Over the past few years controversy has continued as to whether alkylating agents such as cyclophosphamide or chlorambucil are as effective as cisplatin in advanced ovarian cancer. Arguments have also been put forward against the use of combination chemotherapy, which is clearly more toxic than single-agent treatment and is probably no more effective than a single-agent platinum compound except in terms of producing a higher response rate. Certainly survival is not improved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Brade WP, Herdrich K, Varini M (1985) Ifosfamide — pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1–47
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju KS, Wiltshaw E, Smith IE, Baker JM, Peckham MJ, Harrap KR (1982) Early clinical studies withcis-diammine-1,1-cyclobutane dicarboxylate platinum(II). Cancer Chemother Pharmacol 9: 140–147
Evans BD, Raju KS, Calvert AH, Harland SJ, Wiltshaw E (1983) Phase II study of JM8, a new platinum analog in advanced ovarian carcinoma. Cancer Treat Rep 67:997–1000
Gallagher CJ, Wiltshaw E, Coleman RE, Harper PG (1989) A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer. Cancer Chemother Pharmacol 24:54–57
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Wiltshaw, E., Perren, T.J., Fryatt, I.D. et al. Carboplatin and ifosfamide in ovarian cancer phase II and III trials. Cancer Chemother. Pharmacol. 26 (Suppl 1), S48–S50 (1990). https://doi.org/10.1007/BF00685419
Issue Date:
DOI: https://doi.org/10.1007/BF00685419